...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Oncogene >The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients
【24h】

The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients

机译：吉妥珠单抗Ozogamicin在治疗急性髓细胞性白血病患者中的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Gemtuzumab Ozogamicin (GO) is an antibody-targeted chemotherapy agent consisting of the humanized murine CD33 antibody (clone P67.6) to which the calicheamicin-g1 derivative is attached via a hydrolysable bifunctional linker. GO is able to induce apoptosis in vitro in CD33-expressing cells and it has been approved in USA and in Europe as monotherapy for the treatment of elderly patients (older than 60 years) with relapsed acute myeloid leukemia (AML). GO administered as a single agent has resulted in overall response rates of about 30% in previously relapsed adults AML patients (including also with incomplete platelet recovery). Preliminary data indicate a potential role for GO also as a component of induction or consolidation regimens in adults and children. As for adverse events, veno-occlusive syndrome characterizes its tolerability profile, but GO is comparatively well tolerated by most patients.
机译：Gemtuzumab Ozogamicin（GO）是一种靶向抗体的化疗药物，由人源化鼠CD33抗体（克隆P67.6）组成，其中calicheamicin-g1衍生物通过可水解的双功能接头与之连接。 GO能够在体外表达CD33的细胞中诱导细胞凋亡，并且已在美国和欧洲批准为治疗老年患者（60岁以上）复发性急性髓细胞白血病（AML）的单一疗法。在以前复发的成年AML患者中，GO作为单一药物给药已导致总体缓解率约为30％（包括血小板恢复不完全）。初步数据表明，GO在成人和儿童中也可能作为诱导或巩固方案的一部分。至于不良事件，静脉闭塞综合征是其耐受性的特征，但大多数患者对GO的耐受性相对较好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号